October - December
- Total revenue of
SEK 4,581 M (4,890), -6 per cent (-2 per cent at CER) -
Adjusted EBITA1,2 was
SEK 2,177 M (2,380), with an adjusted EBITA margin1,2 of 48 percent (49) . Adjusted EBITA excludes positive impact from reversal of the CVR liability ofSEK 399 M -
Earnings per share (EPS) of
SEK 5.09 (4.62), before dilution -
Sales for Elocta® were
SEK 1,071 M (1,235) and for Alprolix®SEK 419 M (405) -
Sales for Doptelet® were
SEK 191 M (34) -
Sales for Kineret® were
SEK 586 M (396), for Synagis®SEK 1,432 M (1,656) and for Gamifant®SEK 263 M (180) -
Cash flow from operations of
SEK 858 M (976) - Sobi and Apellis entered collaboration for global co-development and ex-US commercialisation of systemic pegcetacoplan in rare diseases with urgent need for new treatments
January - December
- Total revenue of
SEK 15,261 M (14,248), 7 per cent growth (8 per cent at CER) -
Adjusted EBITA1,2 was
SEK 6,301 M (6,145), an increase of 3 per cent, with an adjusted EBITA margin1,2 of 41 percent (43) -
EPS of
SEK 11.01 (11.29), before dilution -
Sales for Elocta were
SEK 4,585 M (4,508) and for AlprolixSEK 1,705 M (1,463) -
Sales for Doptelet were
SEK 587 M (34) -
Sales for Kineret were
SEK 2,079 M (1,571), for SynagisSEK 2,726 M (2,594 for the period
23 Jan-31 Dec, 2019 ) and for GamifantSEK 609 M (542) -
Cash flow from operations of
SEK 5,214 M (3,634)
Outlook 2021
- Revenue for the full-year 2021 is expected to be in the range of
SEK 14,000-15,000 M - EBITA margin is expected to be in the range of 30-35 per cent of revenue
"2020 was a year of extreme challenges but also great opportunities. The COVID-19 pandemic created a challenging situation for the whole organisation, which did its utmost to serve customers and ensure supply to patients. At the same time, we entered two important strategic partnerships fuelling our pipeline, strengthening our international footprint and enabling strong future growth. We closed the full year 2020 with solid revenue of
Financial Summary
Amounts in SEK M | Q4 2020 | Q4 2019 | Change | Full-year 2020 | Full-year 2019 | Change |
Total revenue | 4,581 | 4,890 | -6% | 15,261 | 14,248 | 7% |
Gross profit | 3,718 | 3,833 | -3% | 12,036 | 10,913 | 10% |
Gross margin1 | 81% | 78% | 79% | 77% | ||
EBITA1 | 2,576 | 2,288 | 13% | 6,700 | 5,933 | 13% |
EBITA adjusted1,2 | 2,177 | 2,380 | -9% | 6,301 | 6,145 | 3% |
EBITA margin1 | 56% | 47% | 44% | 42% | ||
EBITA margin adjusted1,2 | 48% | 49% | 41% | 43% | ||
Profit for the period | 1,502 | 1,360 | 10% | 3,245 | 3,304 | -2% |
Earnings per share, before dilution, SEK | 5.09 | 4.62 | 10% | 11.01 | 11.29 | -2% |
Earnings per share, before dilution, SEK adjusted1,2, 3 | 3.74 | 4.90 | -24% | 9.66 | 11.89 | -19% |
1Alternative Performance Measures (APMs).
2EBITA Q4 and full-year 2020 excluding non-recurring item; other operating income related to the reversal of the CVR liability of
3EPS Q4 and full-year 2020 excluding the reversal of the CVR liability of
Telephone conference:
Investors, financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 13:00 CET. The event will be hosted by Sobi's CEO and President,
To participate in the telephone conference, please call:
SE: +46 8 566 426 95
US: +1 646 722 49 03
Click here to go to the live webcast.
After the live event the webcast will be available on-demand via the same link.
---
About Sobi™
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Sobi employs approximately 1,500 people across
This information is information that
For more information please contact
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com
+ 46 767 248 830
maria.kruse@sobi.com
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-publishes-report-for-the-fourth-quarter-and-full-year-2020,c3289052
https://mb.cision.com/Main/14266/3289052/1374629.pdf
(c) 2021 Cision. All rights reserved., source